BD Strengthens Leadership with New Board Members
BD (Becton, Dickinson and Company) (NYSE: BDX), a globally recognized leader in medical technology, has officially appointed Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors. This significant change will take effect on December 1, 2025.
Expertise in Health Care and Technology
Increasing the board's strength, Huffines and Wright bring extensive knowledge in health care, technology, digital transformation, and finance. Tom Polen, chairman and CEO of BD, expressed optimism about their contributions to advancing BD's strategic goals as a pure-play innovative medical technology company. He emphasized the value these appointments will deliver to BD's shareholders while improving patient health systems.
Insights from New Board Members
Both new additions to the board have expressed enthusiasm about the opportunities ahead. Huffines highlighted BD's role in enhancing health care through innovation. He is committed to fostering sustainable value for all stakeholders as BD enters a pivotal era. Wright echoed these sentiments, reflecting on BD's significant role in patient care over the past century and her eagerness to influence future health care landscapes positively.
Board Refreshment and Governance Commitment
These board changes mark the third independent director appointment for BD in 2025, showcasing the company’s commitment to effective corporate governance and continual board renewal. This strategy reflects BD's recognition of the evolving dynamics within the health care sector.
About Robert Huffines
Bringing over 30 years of vital experience in the health care sector, Robert Huffines has held key positions in investment banking. His tenure as a global chairman of investment banking at J.P. Morgan Chase & Co. solidifies his expertise in mergers, acquisitions, and financing strategies within the industry. In addition to his directorial role at Insulet Corporation, Huffines has founded The Forest Group, Inc., focusing on improving the mental health of underserved youth.
About Jacqueline Wright
Jacqueline Wright boasts over three decades in technology innovation. Her recent role as chief technology and platform officer at McKinsey & Company demonstrates her adeptness in managing large-scale digital transformations. Wright's past experience at Microsoft and the UK's HM Revenue and Customs reflects her profound impact on technology deployment in complex organizational structures.
About BD
BD is a leading medical technology company dedicated to advancing the world of health through superior medical discovery, diagnostics, and care delivery solutions. With 70,000 employees globally, BD focuses on enhancing the safety and efficiency of health care provider processes while enabling better disease detection and therapeutic developments. Committed to tackling significant global health challenges, BD partners with a variety of organizations to improve health care outcomes.
Frequently Asked Questions
Who are the new board members of BD?
The new board members are Robert Huffines and Jacqueline Wright, appointed to strengthen BD's leadership in medical technology.
What is the effective date of the new appointments?
The appointments of Robert Huffines and Jacqueline Wright will take effect on December 1, 2025.
What experience does Robert Huffines bring to the board?
Robert Huffines brings over 30 years of experience in health care advisory, particularly in investment banking, with roles in major firms like J.P. Morgan Chase & Co.
What are Jacqueline Wright's credentials?
Jacqueline Wright has over 30 years in technology and digital transformation, serving in leadership roles at McKinsey & Company and Microsoft.
What is BD's mission as a company?
BD aims to improve health care delivery through innovation in medical technology, enhancing clinical processes, and working to resolve global health challenges.
